Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement

NCT ID: NCT00398905

Last Updated: 2009-05-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 726 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-01-31
• Study Completion Date: 2004-09-30

Brief Summary

Patients undergoing surgery, especially hip and knee surgery, are at high risk for VTE. The administration of drugs for thromboprophylaxis, such as heparins, significantly lowers that risk, but heparins have to be applied by injections below the skin. The purpose of this study was to compare the safety and efficacy of BAY 59-7939 with the safety and efficacy of the licensed drug enoxaparin and to find the optimal dose of BAY 59-7939 for the anticipated phase III trials. Enoxaparin, a so-called low molecular weight heparin, is approved and widely used in the area of thromboprophylaxis and was given once daily subcutaneously. In this study 5 different doses of the investigational drug BAY 59-7939 were tested in comparison to Enoxaparin. The following doses of BAY 59-7939 were tested: 2.5 mg twice daily (5 mg total daily dose); 5 mg twice daily (10 mg total daily dose), 10 mg twice daily (20 mg total daily dose), 20 mg twice daily (40 mg total daily dose) and 30 mg twice daily ( 60 mg total daily dose). This study ran for approximately 7 months in a number of countries. In total, 726 patients were enrolled in this study.

Conditions

Venous Thromboembolism

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

Arm 1

Group Type: EXPERIMENTAL

Rivaroxaban (Xarelto, BAY59-7939)

Intervention Type: DRUG

2,5 mg twice daily (5 mg total daily dose)

Arm 2

Group Type: EXPERIMENTAL

Rivaroxaban (Xarelto, BAY59-7939)

Intervention Type: DRUG

5 mg twice daily (10 mg total daily dose)

Arm 3

Group Type: EXPERIMENTAL

Rivaroxaban (Xarelto, BAY59-7939)

Intervention Type: DRUG

10 mg twice daily (20 mg total daily dose)

Arm 4

Group Type: EXPERIMENTAL

Rivaroxaban (Xarelto, BAY59-7939)

Intervention Type: DRUG

20 mg twice daily (40 mg total daily dose)

Arm 5

Group Type: EXPERIMENTAL

Rivaroxaban (Xarelto, BAY59-7939)

Intervention Type: DRUG

30 mg twice daily (60 mg total daily dose)

Arm 6

Group Type: ACTIVE_COMPARATOR

Enoxaparin

Intervention Type: DRUG

40 mg once daily (40 mg total daily dose)

Interventions

Rivaroxaban (Xarelto, BAY59-7939)

2,5 mg twice daily (5 mg total daily dose)

Intervention Type: DRUG

Rivaroxaban (Xarelto, BAY59-7939)

5 mg twice daily (10 mg total daily dose)

Intervention Type: DRUG

Rivaroxaban (Xarelto, BAY59-7939)

10 mg twice daily (20 mg total daily dose)

Intervention Type: DRUG

Rivaroxaban (Xarelto, BAY59-7939)

20 mg twice daily (40 mg total daily dose)

Intervention Type: DRUG

Rivaroxaban (Xarelto, BAY59-7939)

30 mg twice daily (60 mg total daily dose)

Intervention Type: DRUG

Enoxaparin

40 mg once daily (40 mg total daily dose)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male patients aged 18 years or above and postmenopausal female patients
• Patients scheduled for elective primary total hip replacement (cemented or non-cemented prosthesis
• Patients written informed consent for participation after receiving detailed written and oral previous information to any study specific procedures

Exclusion Criteria

• Any VTE prior to randomization
• Myocardial infarction (MI) or TIA or ischaemic stroke within the last 6 months prior to randomisation
• History of heparin-induced thrombocytopenia, allergy to heparins
• Intracerebral or intraocular bleeding within the last 6 months prior to randomisation
• History of gastrointestinal disease with gastrointestinal bleeding within the last 6 months prior to the study
• History or presence of gastrointestinal disease which could result in an impaired absorption of the study drug (e.g. severe active inflammatory bowel disease, short gut syndrome)
• Amputation of one leg
• Heart insufficiency NYHA III-IV
• Congenital or acquired haemorrhagic diathesis (PT INR/aPTT not within normal limits) including patients with acquired or congenital thrombopathy
• Thrombocytopenia (platelets < 100.000/µl)
• Macroscopic haematuria.
• Allergy to contrast media.
• Severe hypertension (SBP > 200mmHg, DBP > 100 mmHg)
• Impaired liver function (transaminases > 2 x ULN)
• Impaired renal function (serum creatinine > 1.5 x ULN or creatinine clearance < 30 ml/min)
• Active malignant disease
• Presence of active peptic ulcer or gastrointestinal disease with increased risk of gastrointestinal bleeding
• Body weight < 45 kg
• Drug- or alcohol abuse
• Patients who cannot stop therapy ( in the opinion of the investigator/ physician) with anticoagulants (e.g. phenprocoumon, warfarin-sodium, heparins and factor Xa inhibitors other than study medication) and fibrinolytic therapy should be excluded from the study
• Therapy with acetylic salicylic acid or other thrombocyte aggregation inhibitors (e.g. clopidogrel, dipyridamole and ticlopidine) should be stopped one week before enrolment. Patients not able to stop ASA therapy will be excluded
• All other drugs influencing coagulation, (exception: NSAIDs with half life < 17 hrs will be allowed)
• Systemic and topical treatment with azole compounds (e.g. ketoconazole, fluconazole, itraconazole) and other strong CYP3A4 inhibitors e.g. HIV-protease inhibitors. Azole compounds and other strong CYP3A4 inhibitors
• Therapy with another investigational product within 30 days prior start of study
• Planned intermittent pneumatic compression during active treatment period
• Planned epidural anaesthesia with indwelling epidural catheter (spinal or epidural anaesthesia without indwelling catheter are allowed)
• Concomitant participation in another trial or study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bayer

INDUSTRY

Sponsor Role: lead

Responsible Party

Bayer Healthcare AG

Principal Investigators

Bayer Study Director

Role: STUDY_DIRECTOR

Bayer

Locations

Wiener Neustadt, Lower Austria, Austria

Linz, Upper Austria, Austria

Vienna, Vienna, Austria

Baudour, , Belgium

Bruxelles - Brussel, , Belgium

Genk, , Belgium

Huy, , Belgium

Sint-Truiden, , Belgium

Hellerup, , Denmark

Herlev, , Denmark

Hørsholm, , Denmark

Silkeborg, , Denmark

Amiens, , France

Lille, , France

Poitiers, , France

Rheinfelden, Baden-Wurttemberg, Germany

Ulm, Baden-Wurttemberg, Germany

Fürth, Bavaria, Germany

Garmisch-Partenkirchen, Bavaria, Germany

Sommerfeld, Brandenburg, Germany

Frankfurt am Main, Hesse, Germany

Frankfurt am Main, Hesse, Germany

Marburg, Hesse, Germany

Düsseldorf, North Rhine-Westphalia, Germany

Dresden, Saxony, Germany

Berlin, State of Berlin, Germany

Haifa, , Israel

Tel Aviv, , Israel

Tel Litwinsky, , Israel

Ẕerifin, , Israel

Rozzano, Milano, Italy

Gubbio, Perugia, Italy

Milan, , Italy

Pavia, , Italy

Perugia, , Italy

Reggio Emilia, , Italy

Varese, , Italy

Hilversum, , Netherlands

Nijmegen, , Netherlands

Sittard, , Netherlands

Bodø, , Norway

Drammen, , Norway

Notodden, , Norway

Oslo, , Norway

Rjukan, , Norway

Bialystok, , Poland

Gdansk, , Poland

Krakow, , Poland

Lodz, , Poland

Lublin, , Poland

Lublin, , Poland

Warsaw, , Poland

Badalona, Barcelona, Spain

Barcelona, Barcelona, Spain

Barcelona, Barcelona, Spain

Valencia, Valencia, Spain

Gothenburg, , Sweden

Halmstad, , Sweden

Jönköping, , Sweden

Kungälv, , Sweden

London, Greater London, United Kingdom

Countries

Austria; Belgium; Denmark; France; Germany; Israel; Italy; Netherlands; Norway; Poland; Spain; Sweden; United Kingdom

Other Identifiers

10944

Identifier Type: -

Identifier Source: org_study_id